The short version of Research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-24 and is reviewed periodically as new material appears.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
===== Laurasiatheria ===== Order Artiodactyla (even-toed ungulates) Family Antilocapridae Antilocapra americana, pronghorn (2019) Family Balaenidae Balaena mysticetus, bowhead whale (2015) Eubalaena glacialis, North Atlantic right whale (2018) Family Balaenopteridae Balaenoptera acutorostrata, common minke whale (2014) Balaenoptera borealis, sei whale (2018) Balaenoptera musculus, blue whale (2018) Balaenoptera physalus, fin whale (2014) Megaptera novaeangliae, humpback whale (2018) Family Bovidae Ammotragus lervia, Barbary sheep (2019) Antidorcas marsupialis, Springbox (2019) Bison bonasus, European bison (2017) Bos grunniens, yak 2012 () Bos primigenius indicus, zebu or Brahman cattle (2012) Bos primigenius taurus, cow 2009 () Bubalus bubalis, river buffalo (2017) Budorcas taxicolor, Takin (2023) Capra ibex, Goats (2019) Cephalophus harveyi, Harvey's duiker (2019) Connochaetes taurinus, blue wildebeest (2019) Damaliscus lunatus, common tsessebe (2019) Gazella thomsoni, Thomson's gazelle (2019) Hippotragus niger, Sable Antelope (2019) Kobus ellipsiprymnus, Waterbuck (2019) Litocranius walleri, Gerenuk (2019) Oreotragus oreotragus, Klipspringer (2019) Oryx gazella, Gemsbok (2019) Ourebia ourebi, Oribi (2019) Ovis ammon, Argali (2019) Ovis ammon polii, marco polo sheep (2017) Nanger granti, Grant's gazelle (2019) Neotragus moschatus, Suni (2019) Neotragus pygmaeus, Royal antelope (2019) Philantomba maxwellii, Maxwell's duiker (2019) Procapra przewalskii, Przewalski's gazelle (2019) Pseudois nayaur, Bharal (2019) Pseudoryx nghetinhensis, Saola (2025) Raphicerus campestris, Steenbox (2019) Redunca redunca, Bohor reedbuck (2019) Syncerus caffer, African buffalo (2019) Sylvicapra grimmia, common duiker (2019) Tragelaphus, Spiral-horned bovine (2019) Tragelaphus buxtoni, Mountain nyala (2019) Tragelaphus strepsiceros, Greater kudu (2019) Tragelaphus imberbis, Lesser kudu (2019) Tragelaphus spekii, Sitatunga (2019) Tragelaphus scriptus, Bushbuck (2019) Taurotragus oryx, Common eland (2019) Family Camelidae Camelus ferus, Wild Bactrian camel (2007) Family Cervidae Cervus albirostris, Tharold's deer (2019) Elaphurus davidianus, Père David's deer (2018) Muntiacus crinifrons, hairy-fronted muntjac (2019) Muntiacus muntjak, Indian muntjac (2019) Muntiacus reevesi, Reeves's muntjac (2019) Odocoileus hemionus, mule deer (2021) Rangifer tarandus, Reindeer (2017) Rusa alfredi, Visayan spotted deer (2025) Family Delphinidae Tursiops truncatus, bottlenosed dolphin (2012) Neophocaena phocaenoides, finless porpoise (2014) Orcinus orca, killer whale (2015) Sousa chinensis, Indo-Pacific humpback dolphin (2019) Family Eschrichtiidae Eschrichtius robustus, gray whale (2018) Family Giraffidae Giraffa camelopardalis, Giraffe (2019) Giraffa camelopardalis tippelskirchi, Masai giraffe (2019) Okapia johnstoni, Okapi (2019) Family Monodontidae Delphinapterus, beluga whale (2017) Family Moschidae Moschus berezovskii, forest musk deer (2018) Moschus chrysogaster, Alpine musk deer (2019) Family Phocoenidae Neophocaena asiaeorientalis sunameri, East Asian finless porpoise (2024) Neophocaena asiaorientalis asiaorientalis, Yangtze finless porpoise (2024) Family Physeteridae Physeter macrocephalus, sperm whale (2019) Family Suidae Sus scrofa, pig (2012) Family Tragulidae Tragulus javanicus, Java mouse-deer (2019) Order Carnivora Family Felidae Acinonyx jubatus, cheetah (2015) Felis catus, cat (2007) Panthera leo, lion (2013) Panthera pardus, Amur leopard (2016) Panthera tigris tigris, Siberian tiger (2013) Panthera tigris tigris, Bengal tiger (2013) Panthera uncia, snow leopard (2013) Prionailurus bengalensis, leopard cat (2016) Family Canidae Canis familiaris, dog (2005) Canis lupus lupus, wolf (2017). Lycaon pictus, african wild dog (2018) Family Ursidae Ailuropoda melanoleuca, giant panda (2010) Ursus arctos ssp. horribilis, Grizzly bear (2018) Ursus americanus, American black bear (2019) Ursus maritimus, Polar bear (2014) Family Odobenidae Odobenus rosmarus, walrus (2015) Family Phocidae Pusa sibirica, Baikal seal (2024) Pusa caspica, Caspian seal (2024) Phoca vitulina, Harbor seal (2024) Pusa hispida, Ringed seal (2024) Family Mustelidae Enhydra lutris kenyoni, sea otter (2017) Mustela erminea, stoat (2018) Mustela furo, ferret (2014) Pteronura brasiliensis, giant otter (2019) Order Chiroptera Family Megadermatidae Megaderma lyra, greater false vampire bat (2013) Family Mormoopidae Pteronotus parnellii, Parnell's mustached bat (2013) Family Pteropodidae Pteropus vampyrus, fruit bat (2012) Eidolon helvum, Old World fruit bat (2013) Family Rhinolophidae Rhinolophus ferrumequinum, greater horseshoe bat (2013) Family Vespertilionidae Myotis lucifugus, little brown bat (2010) Myotis mystacinus, whiskered bat (2024) Family Phyllostomidae Leptonycteris yerbabuenae, long nosed bat (2020) Leptonycteris nivalis, greater long nosed bat (2020) Musonycteris harrisoni, banana bat (2020) Artibeus jamaicensis, Jamaican fruit bat (2020) Macrotus waterhousii, Waterhouse's leaf-nosed bat (2020 Order Erinaceomorpha, Family Erinaceidae Erinaceus europaeus, western European hedgehog () Order Eulipotyphla, Family Solenodontidae Solenodon parodoxus, Hispaniolan solenodon (2018) Order Perissodactyla (odd-toed ungulates) Family Equidae Equus caballus, horse (2009 2018)
Electrotherapy is the use of electrical energy as a medical treatment. In medicine, the term electrotherapy can apply to a variety of treatments, including the use of electrical devices such as deep brain stimulators for neurological disease. Electrotherapy is a part of neurotherapy aimed at changing the neuronal activity. The term has also been applied specifically to the use of electric current to speed up wound healing. The use of electromagnetic stimulation (EMS) is also widespread for the treatment of muscular pain. Additionally, the term "electrotherapy" or "electromagnetic therapy" has also been applied to a range of alternative medical devices and treatments.
=== Tankmates === The croaking gourami should not be kept with large, aggressive fish, and pairs wells with other small, peaceful fish, as well as with fellow gouramis. Male bettas are known to target this species, so bettas should not be kept as tankmates.
Sources: en.wikipedia.org
=== Research in Utah === Research in the Kopeček Biomedical Polymers Laboratory focuses on: a) Macromolecular therapeutics with emphasis on combination chemotherapy and immunotherapy; b) Macromolecular therapeutics for brain delivery; c) Drug-free macromolecular therapeutics – a new paradigm in nanomedicine where apoptosis is initiated by biorecognition of nanoconjugates at the cell surface and receptor crosslinking; no low molecular weight drug is needed.
Aminoacyl-tRNA synthetase enzymes consume ATP in the attachment tRNA to amino acids, forming aminoacyl-tRNA complexes. Aminoacyl transferase binds AMP-amino acid to tRNA. The coupling reaction proceeds in two steps: aa + ATP ⟶ aa-AMP + PPi aa-AMP + tRNA ⟶ aa-tRNA + AMP The amino acid is coupled to the penultimate nucleotide at the 3′-end of the tRNA (the A in the sequence CCA) via an ester bond (roll over in illustration). Transporting chemicals out of a cell against a gradient is often associated with ATP hydrolysis. Transport is mediated by ATP binding cassette transporters. The human genome encodes 48 ABC transporters, that are used for exporting drugs, lipids, and other compounds.
α-neptunium takes on an orthorhombic structure, resembling a highly distorted body-centered cubic structure. Each neptunium atom is coordinated to four others and the Np–Np bond lengths are 260 pm. It is the densest of all the actinides and the fifth-densest of all naturally occurring elements, behind only rhenium, platinum, iridium, and osmium. α-neptunium has semimetallic properties, such as strong covalent bonding and a high electrical resistivity, and its metallic physical properties are closer to those of the metalloids than the true metals. Some allotropes of the other actinides also exhibit similar behaviour, though to a lesser degree. The densities of different isotopes of neptunium in the alpha phase are expected to be observably different: α-235Np should have density 20.303 g/cm3; α-236Np, density 20.389 g/cm3; α-237Np, density 20.476 g/cm3. β-neptunium takes on a distorted tetragonal close-packed structure. Four atoms of neptunium make up a unit cell, and the Np–Np bond lengths are 276 pm. γ-neptunium has a body-centered cubic structure and has Np–Np bond length of 297 pm. The γ form becomes less stable with increased pressure, though the melting point of neptunium also increases with pressure. The β-Np/γ-Np/liquid triple point occurs at 725 °C and 3200 MPa.
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.